Predict your next investment

KaloCyte company logo
HEALTHCARE | Biotechnology

See what CB Insights has to offer

Founded Year



Unattributed VC | Alive

Total Raised


Last Raised

$300K | 1 yr ago



About KaloCyte

KaloCyte is developing a freeze-dried blood substitute that could be reconstituted and administered to treat traumatic hemorrhage when banked blood is unavailable or undesirable. KaloCyte's ErythroMer red cell substitute is human hemoglobin encapsulated in a synthetic polymer shell. Its design precisely emulates red blood cell oxygen binding/release.

KaloCyte Headquarter Location

670 W Baltimore St HSRF III, 8th Floor

Baltimore, Maryland, 21201,

United States


Latest KaloCyte News

KaloCyte raises $300K from Maryland Momentum Fund

Jun 8, 2020

(Courtesy photo) Less than a year after relocating its headquarters to Baltimore, biotech company KaloCyte has raised new funding from Maryland-based investors and expanded its local team. On Monday, the company announced that it raised $300,000 from the Maryland Momentum Fund, which is a venture fund created by the University System of Maryland that invests in affiliated companies. It is part of a larger funding round for the preclinical-stage company, which is developing an artificial red blood cell substitute. Called ErythroMer, it can be used in situations where stored red blood cells are not available, such as treating trauma when patients have a need for blood. “Blood cell substitutes have been desired for decades, given that fresh blood lasts only a few hours unrefrigerated. KaloCyte’s unique approach to engineering a blood substitute, and the team itself, is world-class. The USM is lucky to have recruited such innovative and entrepreneurial faculty as well as their startup,” said Claire Broido Johnson, managing director of the Maryland Momentum Fund, in a statement. “If KaloCyte is a win, it will be a huge win.” The St. Louis-founded company’s move last fall brought a team to the University of Maryland School of Medicine campus in downtown Baltimore. It also added academic leadership, as cofounder and Chief Scientific Officer Dr. Allan Doctor is directing the recently formed Center for Blood Oxygen Transport & Hemostasis, while cofounder Dr. Dipanjan Pan is leading nanobiofabrication at the center and became a professor at UMSOM and University of Maryland, Baltimore County. The funding will support resources needed for the technical development of the product, and will serve as a bridge to a Series A round being planned for later this year, said President and CEO Elaine Haynes. Since moving to Baltimore last fall, the team has grown from two employees to five full-time employees, including product development scientist Dr. Nivesh Mittal . The company also plans to post a role for a synthetic chemist soon. Advertisement “Our unique location near our founders now at the University of Maryland, Baltimore has allowed the team to achieve substantial progress on the ErythroMer formulation and we’ve expanded the team tapping into the rich talent pool that the area offers,” Haynes said. In May, the company also received a $373,000 Small Business Innovation Research Phase I grant from the National Institutes of Health. Last week, Haynes was named to the 2020 cohort of Springboard Enterprises’ Health Innovation Hub. She joins a network of 800 life sciences entrepreneurs. -30-

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing KaloCyte

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

KaloCyte is included in 2 Expert Collections, including Pharma Startups.


Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.



5,726 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

KaloCyte Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

KaloCyte Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.